SD HEALTHCARERecent and archived news stories on: Biotechnology, Doctors, Drugs, Health Insurance, HMO's/PPO's, Hospitals, Medical Devices, Nursing...
U.S. Reps. Susan Davis and Scott Peters, both Democrats from San Diego, gathered with a group of the region’s medical research stakeholders to solicit Congress to increase funding for the National Institutes of Health, which funds much of the medical research taking place in this area.March 21, 2014 2:18 p.m. $$ Share
Zogenix Inc., the San Diego drugmaker embroiled in controversy over its new opioid painkiller Zohydro ER, finally has a win under its belt — it has successfully blocked an order from Massachusetts Governor Deval Patrick to ban the drug in that state.
The Biotechnology Industry Organization, shortened to BIO, has launched its one-on-one partnering system that will help companies initiate private meetings and gain business contacts at its annual convention, which will be held this June in San Diego.
Stock for San Diego flavor maker Senomyx Inc. rose after signing a new deal with PepsiCo Inc. to develop chemicals that will “restore the desired salty taste in products with reduced salt.”
Biotech: Janssen Labs Is Selective, Not Controlling Of Its Life Science Startups
A Torrey Pines-based life sciences incubator that began two years ago as an “experiment” by pharmaceutical and consumer product giant Johnson & Johnson has today shown more momentum than anyone back then would have imagined.
Biotech: Lack of Market For Biofuels Spurs Flexibility
Biofuels don’t hold the same cachet or glamour they once had, but companies like San Diego’s Genomatica Inc. are showing that the market opportunity is still there for biorenewable products. In particular, specialty chemicals and nutritional supplements are proving to be economically viable industries in the sustainability space.
A jury has ordered medical device maker NuVasive Inc. to pay $30 million to Ventura-based NeuroVision Medical Products Inc. for infringing on the trademark “NeuroVision.”
Biotech and tech stocks have been in a slump for the past three weeks, evidenced in part by the 3.1 percent drop in the Nasdaq Composite — the worst one day percentage decline, according to MarketWatch, since November 2011.
The Food and Drug Administration has halted the study of Halozyme Therapeutics Inc.’s pancreatic cancer treatment trial, just few days after the company voluntary stopped patient enrollment in the drug’s clinical trials.
The California Department of Public Health could fine Palomar Health up to $250,000 in connection with the theft of flash drives containing patient data.
Lumena Pharmaceuticals Inc. has filed for a $75 million initial public offering, just a few weeks after it closed a $45 million Series B financing round.
Kaiser Permanente has named Jane Finley to the position of senior vice president and executive director for the San Diego area.
Zogenix Inc. filed a lawsuit in the U.S. District Court in Massachusetts, the company said, seeking a temporary restraining order barring actions announced by Gov. Deval Patrick — namely, a prohibition against prescribing and dispensing Zohydro ER, Zogenix’s painkiller that was approved last year by the Food and Drug Administration.
Vital Therapies Inc. lowered the proposed size of its planned initial public offering, according to Renaissance Capital. Vital Therapies now plans to sell 4.5 million shares at $13 to $15 per share, expecting to raise about $63 million.
The newly formed San Diego cancer drugmaker Seragon Pharmaceuticals Inc. has appointed Debasish Roychowdhury as its new acting chief medical officer.
A startup company at work on a unique medical device — a photosynthetic scaffold technology that helps restore damaged or diseased tissue — won a university business competition and $6,000.